Q-omics provides the consensus-scored GTF3C6 profile across patient tissues and cancer cell-line models. GTF3C6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GTF3C6 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GTF3C6 protein abundance shows 20,705 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KIRC, and LSCC as cancer lineages where GTF3C6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF3C6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF3C6 survival associations across molecular data types. GTF3C6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF3C6 RNA expression–survival associations across cancer types. High GTF3C6 expression shows unfavorable associations in LIHC, LUAD, KICH, ACC, SCLC and UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GTF3C6 RNA expression.
This table summarizes GTF3C6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GTF3C6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF3C6 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, LUAD, UCEC and STAD. The KIRC box plot shows higher GTF3C6 RNA expression in tumor versus normal tissue (log2 FC = +0.498, t-test p < 0.001).
This table shows molecular features associated with GTF3C6 in patient tissues and cancer cell lines. In patient samples, GTF3C6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF3C6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
